

COPY

Docket Nos. 2316.1002-000; 2316.1003-000; 2316.1004-000;
2316.1007-000 and 2316.1008-000

ASSIGNMENT OF UNITED STATES PATENTS AND PATENT APPLICATIONS

Whereas, **Austrian Nordic Biotherapeutics AG**, a corporation existing under the laws of the country of **AUSTRIA**, having a place of business in **Veterinaerplatz 1, A-1210 Vienna, AUSTRIA** (hereinafter "Assignor") an owner of a certain entire right, title and interest in and to the United States Letters Patents and Patent Applications described in Schedule A attached hereto and made a part hereof (hereinafter "Patents") as set forth in the Assignment recorded on November 2, 2000, Reel 011231, Frames 0589-0594; and

Whereas, **GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH**, a corporation existing under the laws of the country of **GERMANY**, having a place of business in **Ingolstaedter Landstrasse 1, D-85764 Neuherberg, GERMANY** (hereinafter "Assignee") is desirous of acquiring the entire right, title and interest in and to the Patents.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Assignor has sold, assigned and transferred, and by these presents does hereby sell, assign and transfer Assignor's entire right, title and interest in and to the Patents and all reissues and extensions therof, including all claims, if any, which may have arisen for infringement of the patents prior to the date of this assignment, all said rights to be held and enjoyed by the Assignee for its own use and for the use of its successors, assigns or other legal representatives, to the full end of the term for which the Patents have been or will be granted, extended or reissued, as fully and entirely as the same would have been held and enjoyed by the Assignor if this assignment and sale had not been made.



Assignor further agrees that Assignor will, without demanding any further consideration therefor, at the request but at the expense of Assignee, do all lawful and just acts, including the execution and acknowledgment of instruments, that may be or become necessary for obtaining, sustaining, or reissuing the Patents, and for maintaining and perfecting Assignee's right to the Patents.

-2-

IN WITNESS WHEREOF, Assignor has caused these presents to be signed by its duly authorized officer below named effective as of the date written below.

ACCEPTED BY:

GSF-Forschungszentrum Fuer Umwelt und Gesundheit GmbH

By: 


i.v. M. Reichel i.A. Dr. J.K. Gerber
Head of the Legal Dept. Manager of Patents and Technology
Tildreiter der Rechtsabteilung Patente und Technologietransfer

Date: 27. August 2003 27. August 2003Witness: 


i.A. Laschke Syndikus und
Rechtsanwalt - Attorney
Address: Ingolstaedter Landstrasse 1
D-85764 Neuherberg

Date: 27. August 200327. August 2003

Austrian Nordic Biotherapeutics AG

By: 

Name

Title: CEO, VerstandDate: 11 August 2003Witness: Date: 11/8-03Address: 
Vandk. Allé 27
DK- 2720 Vanløse

-3-

SCHEDULE A

UNITED STATES PATENTS

<u>FILE NUMBER</u>	<u>PATENT NO.</u>	<u>ISSUE DATE</u>	<u>TITLE</u>	
316,1004-000 JSF97-04A)	6,117,681	September 12, 2000	Pseudotyped Retroviral Particles	5

UNITED STATES PATENT APPLICATIONS

<u>FILE NUMBER</u>	<u>SERIAL NO.</u>	<u>FILING DATE</u>	<u>TITLE</u>
316,1002-000 JSF97-02A)	08/925,214	September 8, 1997	Vectors That Repress Heterologous Promoter Activity
316,1003-000 JSF07-03A)	08/999,690	September 8, 1997	Vectors Carrying Therapeutic Genes Encoding Antimicrobial Peptides For Gene Therapy
316,1007-000 JSF98-01A)	09/035,596	March 5, 1998	The Use of the WAP or MMTV Regulatory Sequences For Targeted Expression of Linked Heterologous Genes in Human Mammary Cells, Including Human Mammary Carcinoma Cells
316,1008-000 JSF98-02A)	09/058,546	April 10, 1998	Retroviral Vectors Carrying Senescent Cell Derived Inhibitors 1 (SDI-1) or Antisense SDI-1 Nucleotide Sequences